S&P ASX All Technology

US Dollar vs AUD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

QNCX Quince Therapeutics Inc

1.85

0.09 (5.11%)

21 Dec 2024 - Closed

Delayed by 15 minutes

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Nov 2024 to Dec 2024

Click Here for more Quince Therapeutics Charts.

Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Dec 2023 to Dec 2024

Click Here for more Quince Therapeutics Charts.

Quince Therapeutics Inc News

Form S-3 - Registration statement under Securities Act of 1933
Thursday 19 December 2024 (3 days ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 14 November 2024 (1 month ago) • Edgar (US Regulatory)

Form SC 13D - General Statement of Acquisition of Beneficial Ownership
Thursday 14 November 2024 (1 month ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Thursday 14 November 2024 (1 month ago) • Edgar (US Regulatory)

Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
Thursday 14 November 2024 (1 month ago) • Business Wire

Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research
Wednesday 13 November 2024 (1 month ago) • Business Wire

Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting
Tuesday 12 November 2024 (1 month ago) • Business Wire

Quince Therapeutics to Participate at Upcoming Investor Conferences
Tuesday 15 October 2024 (2 months ago) • Business Wire

Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Wednesday 4 September 2024 (4 months ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 22 August 2024 (4 months ago) • Edgar (US Regulatory)

Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)
Thursday 15 August 2024 (4 months ago) • Business Wire

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Wednesday 14 August 2024 (4 months ago) • Edgar (US Regulatory)

More Quince Therapeutics Inc News Articles

AUD vs US Dollar

Westpac Banking

Newcrest Mining

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions